Dimerix Ltd - Asset Resilience Ratio

Latest as of June 2025: 74.89%

Dimerix Ltd (DXB) has an Asset Resilience Ratio of 74.89% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$68.28 Million
Cash + Short-term Investments

Total Assets

AU$91.18 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2025)

This chart shows how Dimerix Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Dimerix Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$68.28 Million 74.89%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$68.28 Million 74.89%

Asset Resilience Insights

  • Very High Liquidity: Dimerix Ltd maintains exceptional liquid asset reserves at 74.89% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Dimerix Ltd Industry Peers by Asset Resilience Ratio

Compare Dimerix Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Zelluna ASA
OL:ZLNA
Biotechnology 75.65%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Dimerix Ltd (2002–2025)

The table below shows the annual Asset Resilience Ratio data for Dimerix Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 74.89% AU$68.28 Million AU$91.18 Million +5.87pp
2024-06-30 69.02% AU$22.14 Million AU$32.08 Million +24.02pp
2023-06-30 45.01% AU$7.99 Million AU$17.76 Million -13.37pp
2022-06-30 58.37% AU$9.63 Million AU$16.50 Million +2.64pp
2021-06-30 55.73% AU$5.25 Million AU$9.42 Million -19.21pp
2020-06-30 74.94% AU$7.79 Million AU$10.39 Million +2.82pp
2019-06-30 72.12% AU$3.56 Million AU$4.94 Million -14.38pp
2018-06-30 86.50% AU$6.28 Million AU$7.26 Million +8.35pp
2017-06-30 78.16% AU$2.24 Million AU$2.87 Million +44.28pp
2013-06-30 33.88% AU$594.05K AU$1.75 Million -50.95pp
2012-06-30 84.83% AU$1.03 Million AU$1.21 Million +58.22pp
2011-06-30 26.60% AU$424.00K AU$1.59 Million +10.73pp
2002-06-30 15.87% AU$300.00K AU$1.89 Million --
pp = percentage points

About Dimerix Ltd

AU:DXB Australia Biotechnology
Market Cap
$167.80 Million
AU$237.16 Million AUD
Market Cap Rank
#18625 Global
#499 in Australia
Share Price
AU$0.40
Change (1 day)
-3.66%
52-Week Range
AU$0.30 - AU$0.76
All Time High
AU$0.77
About

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more